SUNNYVALE, Calif., Dec. 11, 2012 /PRNewswire/ -- Amarantus Bioscience, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced the launch of a suite of online digital corporate communication channels to maintain on-going direct communication with shareholders. The Company has launched official portals on various social media channels including Facebook, Twitter, LinkedIn, Google+ and The Chairman's Blog. The Chairman's Blog is an online communication portal where Amarantus executives will be able to address important topics as they relate to the treatment of apoptosis-related disorders such as Parkinson's and Traumatic Brain Injury, as well as specific points of discussion as they relate to key events at Amarantus. President & CEO Gerald E. Commissiong penned the Company's inaugural blog post " MANF: Arresting cell death in Parkinson's disease, Traumatic Brain Injury, Cardiac Ischemia and more." The blog post can be found online at the official Amarantus Chairman's Blog profile provided below. "In this environment where there is an increasing need for open dialog and transparency with shareholders, the channels implemented today will allow for streamlined and efficient communication with our shareholders, while maintaining compliance with all securities laws," said Gerald E. Commissiong, President & CEO of Amarantus. "The Chairman's Blog will allow us to have a more open dialogue and give us additional ways to interact with our base." Links to the new communication tools are here: • Facebook: https://www.facebook.com/amarantusbio • Twitter: https://twitter.com/AmarantusBio • LinkedIn: http://www.linkedin.com/company/2467217?trk=tyah • Google+: https://plus.google.com/u/1/b/110152688579338796390/110152688579338796390/posts • Chairman's Blog Profile: http://www.thechairmansblog.com/author/gerald-commissiongAbout Amarantus Bioscience, Inc. Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. This press release does not represent an offer to buy or sell securities.